AR 26Alternative Names: AR26
Latest Information Update: 12 Oct 2016
At a glance
- Originator Arbor Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Psychiatric disorders
Most Recent Events
- 12 Oct 2016 Phase-II clinical trials in Psychiatric disorders (unspecified route) (Arbor Pharmaceuticals pipeline, October 2016)